View in EDS

Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1.

Saved in:
Bibliographic Details
Title: Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1.
Authors: Naidoo J; Department of Medicine, Beaumont Hospital Dublin, RCSI University of Medicine and Health Science, Dublin, Ireland. Electronic address: jarushkanaidoo@beaumont.ie., Peters S; Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne University, Lausanne, Switzerland. Electronic address: solange.peters@chuv.ch., Runglodvatana Y; Division of Medical Oncology, Department of Internal Medicine, Vajira Hospital, Bangkok, Thailand. Electronic address: kanakorn@nmu.ac.th., Li JY; Department of Clinical Oncology, Hong Kong United Oncology Centre, Kowloon, Hong Kong, China. Electronic address: ycli@hkuoc.hk., Fong CH; Department of Radiotherapy and Oncology, Hospital Pulau Pinang, Penang, Malaysia. Electronic address: fongchinheng@gmail.com., Ho GF; Clinical Oncology Unit, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia. Electronic address: gfho@curieoncology.com.my., How SH; Department of Medicine, Hospital Tengku Ampuan Afzan, Pahang, Malaysia. Electronic address: how_sh@yahoo.com., Juengsamarn J; Oncology Unit, Department of Medicine, Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand. Electronic address: jittyjungnut@gmail.com., Graham JR; Arcus Biosciences, Inc., Hayward, CA, United States. Electronic address: jgraham@arcusbio.com., Marina N; Arcus Biosciences, Inc., Hayward, CA, United States. Electronic address: nmsmarina@gmail.com., Dang T; Gilead Sciences, Inc., Foster City, CA, United States. Electronic address: thao.dang1@gilead.com., Patel D; Arcus Biosciences, Inc., Hayward, CA, United States. Electronic address: pat.deepa.s@gmail.com., Han S; Arcus Biosciences, Inc., Hayward, CA, United States. Electronic address: shan@arcusbio.com., Bermingham C; Arcus Biosciences, Inc., Hayward, CA, United States. Electronic address: cbermingham@arcusbio.com., Johnson ML; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, United States. Electronic address: melissa.johnson@scri.com.
Source: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2026 May; Vol. 215, pp. 109316. Date of Electronic Publication: 2026 Feb 11.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41830668
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Naidoo+J%22">Naidoo J</searchLink>; Department of Medicine, Beaumont Hospital Dublin, RCSI University of Medicine and Health Science, Dublin, Ireland. Electronic address: jarushkanaidoo@beaumont.ie.<br /><searchLink fieldCode="AU" term="%22Peters+S%22">Peters S</searchLink>; Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne University, Lausanne, Switzerland. Electronic address: solange.peters@chuv.ch.<br /><searchLink fieldCode="AU" term="%22Runglodvatana+Y%22">Runglodvatana Y</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Vajira Hospital, Bangkok, Thailand. Electronic address: kanakorn@nmu.ac.th.<br /><searchLink fieldCode="AU" term="%22Li+JY%22">Li JY</searchLink>; Department of Clinical Oncology, Hong Kong United Oncology Centre, Kowloon, Hong Kong, China. Electronic address: ycli@hkuoc.hk.<br /><searchLink fieldCode="AU" term="%22Fong+CH%22">Fong CH</searchLink>; Department of Radiotherapy and Oncology, Hospital Pulau Pinang, Penang, Malaysia. Electronic address: fongchinheng@gmail.com.<br /><searchLink fieldCode="AU" term="%22Ho+GF%22">Ho GF</searchLink>; Clinical Oncology Unit, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia. Electronic address: gfho@curieoncology.com.my.<br /><searchLink fieldCode="AU" term="%22How+SH%22">How SH</searchLink>; Department of Medicine, Hospital Tengku Ampuan Afzan, Pahang, Malaysia. Electronic address: how_sh@yahoo.com.<br /><searchLink fieldCode="AU" term="%22Juengsamarn+J%22">Juengsamarn J</searchLink>; Oncology Unit, Department of Medicine, Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand. Electronic address: jittyjungnut@gmail.com.<br /><searchLink fieldCode="AU" term="%22Graham+JR%22">Graham JR</searchLink>; Arcus Biosciences, Inc., Hayward, CA, United States. Electronic address: jgraham@arcusbio.com.<br /><searchLink fieldCode="AU" term="%22Marina+N%22">Marina N</searchLink>; Arcus Biosciences, Inc., Hayward, CA, United States. Electronic address: nmsmarina@gmail.com.<br /><searchLink fieldCode="AU" term="%22Dang+T%22">Dang T</searchLink>; Gilead Sciences, Inc., Foster City, CA, United States. Electronic address: thao.dang1@gilead.com.<br /><searchLink fieldCode="AU" term="%22Patel+D%22">Patel D</searchLink>; Arcus Biosciences, Inc., Hayward, CA, United States. Electronic address: pat.deepa.s@gmail.com.<br /><searchLink fieldCode="AU" term="%22Han+S%22">Han S</searchLink>; Arcus Biosciences, Inc., Hayward, CA, United States. Electronic address: shan@arcusbio.com.<br /><searchLink fieldCode="AU" term="%22Bermingham+C%22">Bermingham C</searchLink>; Arcus Biosciences, Inc., Hayward, CA, United States. Electronic address: cbermingham@arcusbio.com.<br /><searchLink fieldCode="AU" term="%22Johnson+ML%22">Johnson ML</searchLink>; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, United States. Electronic address: melissa.johnson@scri.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228800805%22">Lung cancer (Amsterdam, Netherlands)</searchLink> [Lung Cancer] 2026 May; Vol. 215, pp. 109316. <i>Date of Electronic Publication: </i>2026 Feb 11.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Scientific+Publishers%22">Elsevier Scientific Publishers </searchLink><i>Country of Publication: </i>Ireland <i>NLM ID: </i>8800805 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1872-8332 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201695002%22">01695002 </searchLink><i>NLM ISO Abbreviation: </i>Lung Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41830668
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.lungcan.2026.109316
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 109316
    Titles:
      – TitleFull: Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Naidoo J
      – PersonEntity:
          Name:
            NameFull: Peters S
      – PersonEntity:
          Name:
            NameFull: Runglodvatana Y
      – PersonEntity:
          Name:
            NameFull: Li JY
      – PersonEntity:
          Name:
            NameFull: Fong CH
      – PersonEntity:
          Name:
            NameFull: Ho GF
      – PersonEntity:
          Name:
            NameFull: How SH
      – PersonEntity:
          Name:
            NameFull: Juengsamarn J
      – PersonEntity:
          Name:
            NameFull: Graham JR
      – PersonEntity:
          Name:
            NameFull: Marina N
      – PersonEntity:
          Name:
            NameFull: Dang T
      – PersonEntity:
          Name:
            NameFull: Patel D
      – PersonEntity:
          Name:
            NameFull: Han S
      – PersonEntity:
          Name:
            NameFull: Bermingham C
      – PersonEntity:
          Name:
            NameFull: Johnson ML
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2026 May
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1872-8332
          Numbering:
            – Type: volume
              Value: 215
          Titles:
            – TitleFull: Lung cancer (Amsterdam, Netherlands)
              Type: main
ResultId 1